Health Condition 1: C81-C96- Malignant neoplasms of lymphoid, hematopoietic and related tissue Health Condition 2: C729- Malignant neoplasm of central nervous system, unspecified Health Condition 3: C717- Malignant neoplasm of brain stem Health Condition 4: C715- Malignant neoplasm of cerebral ventricle Health Condition 5: C74- Malignant neoplasm of adrenal gland
Conditions
Interventions
Intervention1: Nil: Nil
Intervention2: Nil: Nil
Control Intervention1: Nil: Nil
Sponsors
Dr Rajiv Sarin
Centre of Advanced Research Grant from Indian Council for Medical Research
Eligibility
Inclusion criteria
Inclusion criteria: 1. Age at first cancer diagnosis less than equal to 18 years 2. Histopathologically confirmed cancer diagnosis 3. Patients in whom tumour biopsy is not possible or mandatory due to location or nature of tumour (such as brain stem or optic pathway glioma, intraocular tumours or specific liver or germ cell tumors) should have an unequivocal diagnosis of a specific cancer based on pathognomonic Clinico Radiological features including or excluding elevated tumor markers. 4. Diagnosed with primary, second primary or relapsed cancer in the previous 6 months, with exceptions made to include rare cancers like choroid plexus carcinoma, adrenocortical carcinoma at any time from diagnosis. 5. Parents or patients (more than 18 years) informed consent for the study
Exclusion criteria
Exclusion criteria: Incomplete or inconclusive histological, cytogenetic or molecular examination needed to establish an unequivocal diagnosis of cancer and its subtype
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| To study the prevalence and spectrum of pathogenic germline mutations in cancer predisposition genes in 3 distinct groups of childhood cancer (CNS, Haematolymphoid, and Pediatric solid tumours) not selected for family history or syndromic features.Timepoint: Post-enrollment, typically after the sample is processed and results reported. Sampling is expected within the study duration after whole exome sequencing/whole genome sequencing. Survival will be calculated at the end of study period from the time of primary malignancy diagnosis (for relapse patients in the study, from the date of diagnosis of first malignancy) to the occurrence of relapse, progression, death, or the occurrence of second malignant neoplasm or last follow up if no events occur | — |
Secondary
| Measure | Time frame |
|---|---|
| 1. Based on the frequency of germline mutation in different CPS genes, develop and validate new targeted multigene panels 2. Identify and validate new CPS Genes 3. To study the genotype-phenotype correlation of pathogenic variants in specific genes and gene spectrum in specific cancer subtypes 4. Identify any hotspot or founder germline mutation in various Geo-ethnic groups in India and the prevalence of such mutations in distinct population groups 5. Compliance for cascade testing in families with an identified mutation, identifying barriers for noncompliance & developing strategies to overcome these 6. Compliance for high-risk screening and prevention recommended to mutation carriers, identifying barriers for noncompliance & developing strategies to overcome these 7. Correlation of germline variants in specific genes with clinical outcome - response, acute and late toxicity to specific drugs and radiation; event-free and overall survivalTimepoint: Throughout treatment and follow-up; final analysis at study end. | — |
Countries
India
Contacts
Public ContactDr Rajiv Sarin
Tata Memorial Centre
Outcome results
None listed